Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28029071 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL187021 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| Bromide SCHEMBL6336611 | 0.98 | LMNA (0.46) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL38896 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL29355171 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL23067650 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL29754090 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL2315458 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL31150922 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1PDE4A | |
| SCHEMBL7172534 | 0.93 | LMNA (0.52) | LMNAL3MBTL1TDP1AKR1B1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592309-B2 | Positron emission tomography probe to monitor selected sugar metabolism in vivo | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-14 | — | — | US | claimed |
| US-20150133777-A1 | POSITRON EMISSION TOMOGRAPHY PROBE TO MONITOR SELECTED SUGAR METABOLISM IN VIVO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | claimed |
| WO-2013170085-A1 | A POSITRON EMISSION TOMOGRAPHY PROBE TO MONITOR SELECTED SUGAR METABOLISM IN VIVO | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-14 | — | — | WO | claimed |
| US-20130078218-A1 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. | 2013-03-28 | — | — | US | claimed |
| EP-2537520-A1 | Hepatics C therapies | Biocryst Pharmaceuticals, Inc. (US) | 2012-12-26 | — | — | EP | claimed |
| EP-2535345-A1 | Anticancer nucleoside analogs | BioCryst Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | claimed |
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | claimed |
| JP-2011525171-A | — | — | 2011-09-15 | — | — | JP | claimed |
| WO-2006104945-A2 | HEPATITIS C THERAPIES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | WO | claimed |
| EP-1676853-A1 | ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E | YAMASA CORPORATION (JP) | 2006-07-05 | — | — | EP | claimed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| EP-1088066-A1 | ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON BETA-ARABINOFURANOSE AND ITS ANALOGUES | McGILL UNIVERSITY (CA) | 2001-04-04 | — | — | EP | claimed |
| WO-1999067378-A1 | ANTISENSE OLIGONUCLEOTIDE CONSTRUCTS BASED ON β-ARABINOFURANOSE AND ITS ANALOGUES | MCGILL UNIVERSITY (CA) | 1999-12-29 | — | — | WO | claimed |
| EP-0674706-B1 | KDO ALDOLASE AND CONDENSATION REACTIONS EMPLOYED THEREWITH | SCRIPPS RESEARCH INST (US) | 1999-06-09 | — | — | EP | claimed |
| US-5585261-A | CONDENSATION OF AN ALDOSE WITH PYRUVIC ACID TO GIVE2-KETO-3-DEOXY-ONIC ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-12-17 | — | — | US | claimed |
| EP-0674706-A1 | KDO ALDOLASE AND CONDENSATION REACTIONS EMPLOYED THEREWITH | THE SCRIPPS RESEARCH INSTITUTE (US) | 1995-10-04 | — | — | EP | claimed |
| US-5358859-A | From d-arabinose and pyruvate | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-10-25 | — | — | US | claimed |
| WO-1994014954-A2 | KDO ALDOLASE AND CONDENSATION REACTIONS EMPLOYED THEREWITH | THE SCRIPPS RESEARCH INSTITUTE (US) | 1994-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133777-A1 | POSITRON EMISSION TOMOGRAPHY PROBE TO MONITOR SELECTED SUGAR METABOLISM IN VIVO | FBP1, DERA, MPI | LMNA 4417/4885L3MBTL1 2334/4885TDP1 2537/4885 |
| US-20130078218-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | LMNA 2775/4885L3MBTL1 3091/4885TDP1 4685/4885 |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | LMNA 2472/4885L3MBTL1 2852/4885TDP1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.